Merck KGaA Boosts Earnings Forecast on Strong Demand and New Acquisition
Merck KGaA has raised its earnings forecast for 2026 after posting better-than-expected quarterly results in its Life Science and Electronics units. The German company, which is a diversified family-controlled group, expects its earnings before interest, taxes, depreciation, and amortization (EBITDA) to rise between €5.9 billion and €6.3 billion ($6.8-7.3 billion), up from the previously expected range of €5.7 billion to €6.1 billion.
This updated forecast is driven by strong demand for Merck's drug manufacturing supplies and semiconductor materials, which are used in various industries such as biotechnology and electronics. The company's Life Science unit, in particular, has seen significant growth due to its research and manufacturing tools.
In June, Merck made a major acquisition when it struck an $11.3 billion deal to buy Bio-Techne, a move that will add additional capabilities across research, bioprocessing, and advanced therapeutics to the company's portfolio.